Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.

We conducted a systematic reviewand individual patient data (IPD) meta-analysisto evaluate the impact of achieving pathologic complete response (pCR) or major pathologic response (MPR) on event-free survival (EFS) and assessed the influence of adjuvant immunotherapy.

我们进行了一项系统评价和个体患者数据(IPD)荟萃分析，以评估实现病理完全缓解(pCR)或主要病理缓解(MPR)对无事件生存(EFS)的影响，并评估了辅助免疫治疗的影响。

Methods

We performed an IPD meta-analysisof prospective clinical trials on neoadjuvant or perioperative anti-programmed death-ligand 1 in combination with platinum-based chemotherapy in patients with resectable NSCLC.

我们对接受新辅助或围手术期抗程序性死亡配体1联合铂类化疗的可切除非小细胞肺癌患者的前瞻性临床试验进行了个体患者数据(IPD)荟萃分析。

The IPD was extracted from Kaplan-Meier curves for pCR and MPR from the included studies.

从纳入研究中提取的个体患者数据(IPD)是从Kaplan-Meier曲线中获取的，用于pCR和MPR。

Survival outcomes were compared between patients achieving pCR or MPR and those who did not, considering both intention-to-treatand resected populations.

在考虑意向治疗和切除人群的情况下，比较了实现pCR或MPR的患者与未实现的患者的生存结果。

Results

Achieving pCR or MPR was associated with improved EFS in the intention-to-treatpopulation (pCR, hazard ratio= 0.13; MPR, hazard ratio= 0.18, respectively) with a 24 months EFS rate of 94% and 88% for patients who achieved pCR and MPR, respectively.

在意向治疗人群中，实现pCR或MPR与EFS的改善相关（pCR，风险比=0.13；MPR，风险比=0.18），实现pCR和MPR的患者的24个月EFS率分别为94%和88%。

Independently from pCR status, patients who were treated in an experimental arm that included adjuvant immunotherapy had similar EFS.

无论pCR状态如何，接受包括辅助性免疫治疗在内的实验性治疗方案的患者，其无进展生存期（EFS）相似。

Conclusions

Our study reported a strong EFS improvement in patients who achieved either pCR or MPR after neoadjuvant chemoimmunotherapy.

我们的研究报道了在接受新辅助化疗免疫治疗后达到pCR或MPR的患者中，无进展生存期（EFS）有显著改善。

The use of adjuvant immunotherapy after tumor resection was not associated with improved EFS.

肿瘤切除后辅助性免疫治疗的使用与无进展生存期（EFS）的改善无相关性。